PMC:7228307 / 842-1253
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
20 | 98-102 | Gene | denotes | FcγR | Gene:2213 |
23 | 347-394 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
24 | 396-406 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
27 | 285-292 | Disease | denotes | cancers | MESH:D009369 |
28 | 294-315 | Disease | denotes | inflammatory diseases | MESH:D007249 |
29 | 328-338 | Disease | denotes | infections | MESH:D007239 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T7 | 3-12 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T3 | 294-315 | Disease | denotes | inflammatory diseases | http://purl.obolibrary.org/obo/MONDO_0021166 |
T4 | 328-338 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T5 | 347-394 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 347-380 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 396-400 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T11 | 55-58 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T12 | 73-74 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T13 | 98-100 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T6 | 307-315 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | diseases |
T7 | 328-338 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
20 | 98-102 | Gene | denotes | FcγR | Gene:2213 |
23 | 347-394 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
24 | 396-406 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
27 | 285-292 | Disease | denotes | cancers | MESH:D009369 |
28 | 294-315 | Disease | denotes | inflammatory diseases | MESH:D007249 |
29 | 328-338 | Disease | denotes | infections | MESH:D007239 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T2 | 347-394 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | NCBItxid:2697049 |
T3 | 396-406 | Species | denotes | SARS‐CoV‐2 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 27-243 | Sentence | denotes | The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T7 | 3-12 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 294-315 | Disease | denotes | inflammatory diseases | http://purl.obolibrary.org/obo/MONDO_0021166 |
T3 | 328-338 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T4 | 347-394 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 396-406 | Disease | denotes | SARS‐CoV‐2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 27-243 | Sentence | denotes | The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. |